Understanding Weight and Cardiometabolic Health

Medical Disclaimer: This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Information is based on current medical literature and clinical guidelines but may not apply to your specific situation. Individual responses vary based on personal medical history and concurrent conditions. Always consult qualified healthcare providers for medical decisions. Never delay seeking medical care based on content you’ve read. If experiencing a medical emergency, seek immediate medical attention.

These articles provide education to enhance your healthcare partnership. All treatment decisions should involve your healthcare team. Use this knowledge to have informed discussions, not replace medical care.

In Brief

Excess body fat affects the heart through more than added weight — it acts through what fat tissue does biologically. Enlarged, stressed fat, particularly fat stored deep in the abdomen, releases hormones, fatty acids, and inflammatory signals that raise blood pressure, drive insulin resistance, worsen cholesterol, and promote the vascular injury behind heart disease. This is why obesity is increasingly understood as a chronic condition with biological roots rather than a matter of willpower, and why the number on the scale is an incomplete measure of the risk any one person carries — cardiometabolic health can differ substantially from what weight alone suggests. Modest, sustained improvement in the measures that matter — blood pressure, blood sugar, cholesterol, and fitness — meaningfully lowers cardiovascular risk, though whether a given approach reduces hard cardiovascular events depends on how weight is changed, by how much, and in whom. This article establishes what excess adiposity does to the cardiovascular system, why the scale can mislead, and what genuinely improving cardiometabolic health means — the foundation for everything that follows in this series.

Weight Matters to the Heart Because of What Fat Does, Not How It Looks

The everyday view of body weight treats it as a matter of size, appearance, or discipline. For the cardiovascular system, that framing is incomplete. Body weight does matter to the heart and blood vessels — but the number on the scale tells only part of the story. The amount of excess fat matters, and so do where that fat is stored and what the tissue is doing biologically: the hormones it releases, the fatty acids it spills into the bloodstream, and the inflammatory signals it generates.

Adipose tissue — body fat — is not a passive cushion. It is a metabolically active organ that participates directly in blood pressure regulation, blood sugar control, lipid metabolism, and inflammation. When fat cells enlarge and become stressed, especially in the abdomen and around the internal organs, that participation turns harmful. The American Heart Association’s scientific statement on obesity concludes that excess adiposity contributes directly to the major cardiovascular risk factors — abnormal cholesterol, type 2 diabetes, high blood pressure, and sleep-disordered breathing — and that it also contributes to cardiovascular disease and cardiovascular death independently of the risk factors it produces.¹ In other words, obesity is not dangerous only because it raises blood pressure or blood sugar. It appears to injure the cardiovascular system through several routes at once, some of which operate even when the standard numbers still look acceptable.

This has a practical consequence that runs through the entire series. If excess fat harms the heart through what it does — not through weight alone — then the number on the scale is an imperfect guide to risk, and the goal of treatment is not a particular weight but a change in the underlying biology. That distinction shapes what counts as meaningful progress, which measurements actually matter, and how to weigh the growing list of options for improving cardiometabolic health. This is the first of eleven articles in the series, and it establishes the biology on which the rest builds.

Fat Tissue Is an Active Organ, Not Inert Storage

For most of the twentieth century, adipose tissue was regarded as inert storage — a place to bank surplus energy. The discovery in the 1990s of hormones released by fat cells overturned that view. Adipose tissue is now understood as an endocrine organ: it synthesizes and secretes signaling molecules, collectively called adipokines, that travel through the bloodstream and influence insulin sensitivity, appetite, blood pressure, and inflammation throughout the body.²

Two adipokines illustrate the system. Leptin signals the brain about the size of the body’s energy stores and helps regulate appetite. Adiponectin improves the body’s sensitivity to insulin and has anti-inflammatory effects on blood vessels.² In a healthy state, these signals are balanced, and fat tissue expands and contracts without causing systemic harm.

The problem is not fat itself but fat that has become dysfunctional. When adipose tissue can no longer expand and store excess energy without becoming dysfunctional — a tipping point reached sooner for fat in the abdomen — the tissue changes character. Adiponectin levels fall, removing some of its protective, insulin-sensitizing effect. Pro-inflammatory signals rise. Free fatty acids leak into the circulation in greater quantities, and the liver and muscle are exposed to a metabolic environment that blunts their response to insulin.¹,² This is the difference between simply having fat and having fat that is metabolically stressed. It is also why two people carrying the same total weight can face very different levels of risk depending on the state and location of that fat — the subject of Article 2.

In short, overloaded fat tissue sends signals that damage the heart and blood vessels — which is why its biological state, not just its quantity, drives risk.

How Excess Adiposity Reaches the Heart

Excess adiposity does not injure the cardiovascular system through one channel. It feeds a connected sequence — the cardiometabolic cascade — in which dysfunctional fat drives several intermediate problems that then converge on the heart, blood vessels, and kidneys.

The core intermediates are consistent. Insulin resistance, in which cells respond poorly to insulin’s signal, is a central one; it can be described as energy-overflow biology, a state in which the system is chronically handling more fuel than it can cleanly process. Rising blood pressure is another, driven partly by hormonal and nervous-system effects of excess fat and partly by its effects on the kidney and blood vessels. An atherogenic cholesterol pattern is a third — higher triglycerides, lower HDL cholesterol, and an increased burden of atherogenic ApoB-containing particles, often including smaller, denser LDL particles.¹⁴ Low-grade, persistent inflammation runs alongside all of them.¹ None of these is isolated. Each worsens the others, and together they accelerate the cumulative vascular injury that underlies most cardiovascular disease.

Those intermediates then express themselves as specific conditions. The table below summarizes how excess or dysfunctional adiposity contributes to each, and where in the series it is examined in depth. This is the cardiometabolic system that the rest of HeartBuddi maps — obesity is one of its most powerful entry points because it touches so many pathways at once.

How Excess Adiposity Contributes to Cardiometabolic and Cardiovascular Conditions

The mechanisms in this table are drawn from the American Heart Association’s scientific statement, which synthesizes the evidence across these conditions; the strength of the evidence and the size of the benefit from weight change differ by condition, and the table does not imply that treating obesity resolves any of them on its own.¹

The reason this matters clinically is that a person carrying excess visceral fat is rarely dealing with one problem. They are more often accumulating blood pressure, glucose, and lipid abnormalities together, each amplifying the others — which is why obesity so often sits at the center of a cluster rather than standing alone, and why addressing it can influence several risks at once.

This cascade runs from dysfunctional adipose tissue, through the shared intermediates, to the conditions they contribute to. It is best understood as a conceptual map rather than a strict one-directional sequence — the intermediates and conditions reinforce one another.

Why the Scale Is an Incomplete Measure

Body mass index — weight in kilograms divided by height in meters squared — is the conventional screening measure for obesity, with a BMI of 30 or above classified as obesity, 25 to 29.9 as overweight, and 40 or above as severe obesity.⁴ BMI is inexpensive, reproducible, and useful at the population level. But it measures body size, not the biology that determines cardiovascular risk, and it can mislead in both directions.

Reflecting these limitations, a 2025 Lancet Diabetes & Endocrinology Commission — endorsed by more than 75 medical organizations — proposed that obesity be understood as excess adiposity rather than defined by BMI alone, and that BMI not serve as the sole basis for diagnosing it in an individual.⁵ The Commission recommends confirming excess adiposity with direct body-fat measurement where available or, for most people, with an additional anthropometric measure such as waist circumference rather than relying on BMI alone, and it distinguishes clinical obesity — a chronic illness in which excess adiposity is already impairing the function of organs or tissues — from preclinical obesity, in which excess adiposity has not yet caused organ dysfunction but raises future risk.⁵ That framework closely matches the distinction this series draws: what matters is not the number itself but what the excess adiposity is doing, and to whom.

BMI does not distinguish where fat is stored, and location carries much of the risk. In the INTERHEART study — a case-control study of roughly 27,000 people across 52 countries — waist-to-hip ratio, a marker of abdominal fat, showed a graded and strong association with heart attack worldwide, while BMI was only weakly related once other factors were taken into account.³ Two people with the same BMI can carry very different amounts of abdominal fat, and therefore very different risk. This is why measuring the waistline adds information the scale cannot.

The mismatch runs the other way as well. Some people meet the criteria for obesity yet, at a given point in time, show none of the usual metabolic abnormalities — a pattern sometimes called metabolically healthy obesity. It is tempting to read that as reassurance, but the evidence does not support treating it as benign. In an observational study of about 3.5 million adults, people with obesity but no metabolic abnormalities still had a higher risk of coronary heart disease than metabolically healthy people of normal weight — roughly one and a half times higher (hazard ratio 1.49), meaning that if a certain number of heart-disease events would occur in the normal-weight group, close to half again as many occurred in the obese-but-metabolically-healthy group.⁶ Because this is observational data, it describes an association rather than proving that the obesity itself caused the excess events; but the pattern is consistent across large populations.

Part of the explanation is that metabolically healthy obesity is often unstable over time rather than reliably benign. In a separate cohort followed over roughly a decade, about half of people who started as metabolically healthy with obesity went on to develop metabolic syndrome, and it was that transition — and how long it lasted — that tracked with cardiovascular risk.⁷ The reverse pattern also exists: some people at a normal weight carry metabolic abnormalities and elevated risk despite an unremarkable BMI.

The practical lesson is not that BMI is useless but that it is a starting point, not a verdict. Cardiometabolic health is defined by the metabolic profile and fat distribution — blood pressure, blood sugar, cholesterol, waist, and fitness — more than by weight alone. Article 3 examines how each of these is measured and how to build a truer picture than any single number provides.

Why Obesity Is Understood as a Chronic Condition With Biological Roots

The most common assumption about obesity is that it reflects a failure of willpower — that body weight is simply the arithmetic of eating less and moving more, sustained by discipline. The biology tells a more complicated story, and understanding it changes what realistic expectations look like.

The body actively regulates its energy stores through a system called energy homeostasis, which works to match energy intake to energy expenditure and to keep body-fat mass near a defended level over time. The Endocrine Society’s scientific statement on obesity describes the condition as a disorder of this energy-homeostasis system rather than the passive accumulation of excess weight, in which the systems regulating energy intake and expenditure can defend a higher level of body fat — described in the statement as a resetting of the body-weight “set point” at an increased value.⁸ This is why sustained weight loss is biologically difficult: after weight is lost, the system responds as though the body is being starved, increasing hunger and reducing energy expenditure in ways that drive weight back up. People who complete structured weight-loss programs commonly regain much of the lost weight, not because of a lapse in effort but because they are working against a regulated biological response.⁸

None of this means weight cannot change or that effort is pointless. It means the difficulty is physiological, not moral — and framing weight as a matter of character both misreads the biology and, as later articles discuss, actively harms people. It also explains why obesity is increasingly treated by major medical organizations as a chronic condition: like high blood pressure, it tends to require ongoing management rather than a one-time fix, and it has identifiable biological, environmental, and genetic contributors.¹,⁸ Article 8 examines this defended-weight biology in detail, including what happens after lifestyle-induced loss and after medication is stopped.

The relevance of this biology is magnified by how common excess adiposity has become. In the United States, an estimated 40.3% of adults have obesity and 9.4% have severe obesity, based on measured heights and weights from the 2021–2023 National Health and Nutrition Examination Survey.⁴ Globally, a pooled analysis of thousands of population studies estimated that more than one billion people were living with obesity in 2022, with adult obesity more than doubling since 1990 and rates among children and adolescents rising roughly fourfold.⁹ These cardiometabolic pathways are therefore operating, silently, in a large share of the population — often for years before any clinical event.

What Improving Cardiometabolic Health Actually Means

If the goal is not a number on the scale, what is it? It is improvement in the measures that drive cardiovascular risk, and the evidence here is genuinely encouraging — with one important caveat about how benefit is achieved.

Modest weight loss reliably improves cardiometabolic risk factors, and in people at high risk it can prevent diabetes outright. In the Diabetes Prevention Program, a randomized trial in adults with prediabetes, a lifestyle program aiming for at least 7% weight loss and 150 minutes of weekly activity reduced the development of type 2 diabetes by 58% over about three years, compared with placebo — meaning that if roughly 11 of 100 people would have developed diabetes each year, closer to 5 did.¹⁰ That is a large effect from a sustained change in weight and activity, and it is strong randomized evidence that this trajectory can be changed.

The caveat is that improving risk factors is not identical to preventing heart attacks and strokes. In the Look AHEAD trial, more than 5,000 adults who already had type 2 diabetes were randomized to an intensive weight-loss lifestyle program or to standard diabetes support. The program produced real weight loss and better fitness, blood pressure, and blood sugar — yet over nearly a decade it did not significantly reduce the rate of cardiovascular events (about 1.8 versus 1.9 events per 100 person-years), and the trial was stopped early for futility on that endpoint.¹¹ The reasons are likely multifactorial, but the central result stands: improving weight and risk factors did not automatically translate into fewer cardiovascular events. A later analysis of the same trial did find that participants who achieved the largest weight loss — roughly 10% or more — had fewer cardiovascular events, though as an association observed within the trial rather than a benefit the randomized comparison proved.¹²

At the same time, the newest evidence shows that an obesity medication can lower cardiovascular events in the right population. In the SELECT trial, adults with established cardiovascular disease and overweight or obesity but without diabetes who took the GLP-1 medication semaglutide had a 20% lower rate of major cardiovascular events than those on placebo — 6.5% versus 8.0% over about three and a half years, an absolute reduction of roughly 1.5 percentage points — alongside average weight loss near 9%.¹³ The trial was not designed to prove that the weight loss itself caused the benefit, and the medication has effects beyond weight; untangling that is the work of Article 5. But it establishes that, in this specific high-risk group, an obesity treatment reduced hard outcomes.

The three trials are worth seeing side by side, because they separate three questions that discussion of weight loss usually blurs together — preventing diabetes, improving risk factors, and reducing cardiovascular events:

What the Major Weight-Loss Trials Actually Changed

None of these trials was designed to isolate how much of any benefit comes from the weight loss itself versus the specific method used to achieve it — which is why the approach matters, not just the pounds lost.

Put together, the evidence points to a straightforward conclusion. Improving cardiometabolic measures is worthwhile and achievable, and even modest, sustained change lowers risk. Whether a given approach reduces heart attacks and strokes — as opposed to improving the numbers that predict them — depends on how the change is achieved, how large it is, and who the person is. The rest of the series is largely about matching approach to person with that reality in mind.

What a Fuller Picture Includes

Because weight alone is incomplete, clinicians generally consider it alongside waist measurement, blood pressure, glucose, lipids, fitness, and a person’s existing conditions — and they follow the direction of those measures over time rather than fixating on any single value. These are tools for gauging risk, not scores to chase for their own sake. Article 3 examines what each of these adds, and what none of them can establish alone.

Clinical Bottom Line

Excess body fat affects the cardiovascular system through more than weight — it acts through what fat tissue does, releasing hormones, fatty acids, and inflammatory signals that raise blood pressure, drive insulin resistance, worsen cholesterol, and promote vascular injury, and it contributes to heart disease partly independently of the risk factors it produces.¹ This is why obesity is understood as a chronic condition with biological roots rather than a failure of willpower, and why the scale is an incomplete measure: where fat sits and the metabolic profile it produces matter more than total weight, and cardiometabolic health can differ substantially from what BMI suggests.³,⁶,⁸ Modest, sustained improvement in blood pressure, blood sugar, cholesterol, and fitness meaningfully lowers risk and can prevent diabetes,¹⁰ but whether a specific approach reduces heart attacks and strokes depends on how weight is changed, by how much, and in whom.¹¹,¹³ The most useful goal is rarely a number on the scale; it is steady movement in the measures that most affect the heart.

What Comes Next

This article established the foundation: that weight matters to the heart through the biology of fat tissue, that the scale is an incomplete measure of risk, that obesity is a chronic condition with biological roots, and that improving cardiometabolic health means changing the measures that drive cardiovascular disease. Article 2 takes up the first and most important refinement of the scale — why where fat is stored matters more than how much a person weighs, and how fat deep in the abdomen behaves so differently from fat under the skin.

Key Terms

Adipose tissue: Body fat; a metabolically active endocrine organ that stores energy and releases signaling molecules affecting metabolism, appetite, blood pressure, and inflammation — not inert storage.

Adipokines: Signaling molecules (hormones and related proteins) released by adipose tissue that influence insulin sensitivity, appetite, blood pressure, and inflammation throughout the body.

Adiponectin: An adipokine that improves insulin sensitivity and has anti-inflammatory effects on blood vessels; levels tend to fall with excess visceral fat.

Leptin: An adipokine that signals the brain about the size of the body’s energy stores and helps regulate appetite.

Atherogenic dyslipidemia: A cholesterol pattern — typically higher triglycerides, lower HDL cholesterol, and an increased burden of atherogenic ApoB-containing particles (often including smaller, denser LDL) — associated with insulin resistance and excess adiposity.

ApoB (apolipoprotein B): A protein carried on each of the cholesterol particles that drive plaque formation, so the number of ApoB-containing particles reflects atherogenic risk more directly than a single cholesterol value; the Cholesterol series examines it in depth.

BMI (body mass index): Weight in kilograms divided by height in meters squared; a screening measure of body size. Obesity is conventionally defined as a BMI of 30 or above, overweight as 25–29.9, and severe obesity as 40 or above.

Clinical vs. preclinical obesity: A 2025 framework distinguishing obesity that is already impairing organ or tissue function (clinical) from excess adiposity that raises future risk without current organ dysfunction (preclinical).

Cardiometabolic health: The combined state of the measures that determine cardiovascular and metabolic risk — blood pressure, blood sugar, cholesterol, fat distribution, and fitness — which can differ from what body weight alone suggests.

Energy homeostasis: The biological system that matches energy intake to energy expenditure over time and defends body-fat mass near a set level; obesity is understood as a disorder of this system.

Insulin resistance: A reduced cellular response to insulin, so that more insulin is required to manage blood glucose; a central intermediate linking excess adiposity to diabetes and cardiovascular risk.

Metabolically healthy obesity: A pattern in which a person meets criteria for obesity but, at a given time, lacks the usual metabolic abnormalities; often an unstable, transitional state rather than a benign one.

Visceral fat: Fat stored deep in the abdomen and around the internal organs, which is more metabolically active and more strongly associated with cardiovascular risk than fat stored under the skin.

Waist-to-hip ratio / waist circumference: Measures of abdominal fat that add cardiovascular risk information beyond BMI.

References

1. Powell-Wiley TM, Poirier P, Burke LE, et al; American Heart Association Council on Lifestyle and Cardiometabolic Health; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Epidemiology and Prevention; and Stroke Council. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021;143(21):e984–e1010. https://doi.org/10.1161/CIR.0000000000000973
2. Galic S, Oakhill JS, Steinberg GR. Adipose tissue as an endocrine organ. Mol Cell Endocrinol. 2010;316(2):129–139. https://doi.org/10.1016/j.mce.2009.08.018
3. Yusuf S, Hawken S, Ôunpuu S, et al; INTERHEART Study Investigators. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet. 2005;366(9497):1640–1649. https://doi.org/10.1016/S0140-6736(05)67663-5
4. Emmerich SD, Fryar CD, Stierman B, Ogden CL. Obesity and severe obesity prevalence in adults: United States, August 2021–August 2023. NCHS Data Brief No. 508. Hyattsville, MD: National Center for Health Statistics; 2024. https://doi.org/10.15620/cdc/159281
5. Rubino F, Cummings DE, Eckel RH, et al. Definition and diagnostic criteria of clinical obesity. Lancet Diabetes Endocrinol. 2025;13(3):221–262. https://doi.org/10.1016/S2213-8587(24)00316-4
6. Caleyachetty R, Thomas GN, Toulis KA, et al. Metabolically healthy obese and incident cardiovascular disease events among 3.5 million men and women. J Am Coll Cardiol. 2017;70(12):1429–1437. https://doi.org/10.1016/j.jacc.2017.07.763
7. Mongraw-Chaffin M, Foster MC, Anderson CAM, et al. Metabolically healthy obesity, transition to metabolic syndrome, and cardiovascular risk. J Am Coll Cardiol. 2018;71(17):1857–1865. https://doi.org/10.1016/j.jacc.2018.02.055
8. Schwartz MW, Seeley RJ, Zeltser LM, et al. Obesity pathogenesis: an Endocrine Society scientific statement. Endocr Rev. 2017;38(4):267–296. https://doi.org/10.1210/er.2017-00111
9. NCD Risk Factor Collaboration (NCD-RisC). Worldwide trends in underweight and obesity from 1990 to 2022: a pooled analysis of 3663 population-representative studies with 222 million children, adolescents, and adults. Lancet. 2024;403(10431):1027–1050. https://doi.org/10.1016/S0140-6736(23)02750-2
10. Knowler WC, Barrett-Connor E, Fowler SE, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403. https://doi.org/10.1056/NEJMoa012512
11. Look AHEAD Research Group; Wing RR, Bolin P, Brancati FL, et al. Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. N Engl J Med. 2013;369(2):145–154. https://doi.org/10.1056/NEJMoa1212914
12. Look AHEAD Research Group; Gregg EW, Jakicic JM, Blackburn G, et al. Association of the magnitude of weight loss and changes in physical fitness with long-term cardiovascular disease outcomes in overweight or obese people with type 2 diabetes: a post-hoc analysis of the Look AHEAD randomised clinical trial. Lancet Diabetes Endocrinol. 2016;4(11):913–921. https://doi.org/10.1016/S2213-8587(16)30162-0
13. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al; SELECT Trial Investigators. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–2232. https://doi.org/10.1056/NEJMoa2307563
14. Bays HE, Kirkpatrick CF, Maki KC, et al. Obesity, dyslipidemia, and cardiovascular disease: a joint expert review from the Obesity Medicine Association and the National Lipid Association 2024. J Clin Lipidol. 2024;18(3):e320–e350. https://doi.org/10.1016/j.jacl.2024.04.001

HeartBuddi • Your heart. Own it.